Abstract：Objective To evaluate the clinical effect of proton pump inhibitor-based triple therapy combined with Saccharomyces boulardii in the treatment of Helicobacter pylori (Hp) infection among children in terms of Hp eradication rate and incidence of adverse events. Methods A prospective randomised controlled study was conducted on 240 children with a confirmed diagnosis of Hp infection. These patients were randomized into triple therapy (n=120) and probiotics groups (n=120). The triple therapy group received amoxicillin [40 mg/(kg·d), Tid], clarithromycin [15 mg/(kg·d), Bid] and omeprazole [0.7-0.8 mg/(kg·d), Qd], while the probiotics group received Saccharomyces boulardii (250 mg, Bid) in addition to triple therapy. The course of treatment was 14 days in both groups. The adverse events in subjects were recorded by their parents during treatment. Hp eradiation was evaluated by 13C breath test at 4 weeks after treatment, and the eradication rate and incidence of adverse events were compared between the two groups. Results The Hp eradication rates were 75.8% (91/120) in the triple therapy group and 85% (102/120) in the probiotics group (P>0.05). Compared with the triple therapy group, the probiotics group had nonsignificantly lower incidence of nausea, vomiting, and abdominal pain (P>0.05) and significantly lower incidence of stomatitis, constipation and diarrhea (P<0.05). Conclusions Triple therapy combined with Saccharomyces boulardii cannot significantly increase Hp eradication rate, but can significantly reduce the incidence of stomatitis, constipation, and diarrhea during treatment.
ZHAO Hong-Mei,OU-YANG Hong-Juan,DUAN Bo-Ping et al. Clinical effect of triple therapy combined with Saccharomyces boulardii in the treatment of Helicobacter pylori infection in children[J]. CJCP, 2014, 16(3): 230-233.
Go MF, Crowe SE. Virulence and pathogenicity of Helicobacter pylori[J]. Gastroenterol Clin North Am, 2000, 29(3): 649-670.
[3]
Malfertheine P, Megraud F, O' Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht Ⅲ Consensus Report[J]. Gut, 2007, 56(6): 772-781.
[4]
Lionetti E, Indrio F, Pavone L, et al. Role of probiotics in pediatric patients with Helicobacter pylori infection: a comprehensive review of the literature[J]. Helicobacter, 2010, 15(2): 79-87.
[5]
Scaccianoce G, Zullo A, Hassan C, et al. Triple therapies plus different probiotics for Helicobacter pylori eradicaton[J]. Eur Rev Med Pharmacol Sci, 2008, 12(4): 251-256.
[6]
Vandenplas Y, Brunser O, Szajewska H. Saccharomyces boulardii in childhood[J]. Eur J Pediatr, 2009, 168(3): 253-265.
[7]
Rowland M, Daly L, Vaughan M, et al. Age-specific incidence of Helicobacter pylori[J]. Gastroenterology, 2006, 130(1): 65-72.
[8]
Wizla-Derambure N, Michaud L, Ategbo S, et al. Familial and community environmental risk factors for Helicobacter pylori infection in children and adolescents[J]. J Pediatr Gastroenterol Nutr, 2001, 33(1): 58-63.
[9]
Oderda G, Shcherbakov P, Bontems P, et al. European Pediatric Task Force on Helicobacter pylori. Results from the pediatric European register for treatment of Helicobacter pylori (PERTH)[J]. Helicobacter, 2007, 12(2): 150-156.
[10]
Gotteland M, Poliak L, Cruchet S, et al. Effect of regular ingestion of Saccharomyces boulardii plus inulin or Lactobacillus acidophilus LB in children colonized by Helicobacter pylori[J]. Acta Pediatrica, 2005, 94(12): 1-6.
[11]
de Bortoli N, Leonardi G, Ciancia E, et al. Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferin and probiotics[J]. Am J Gastroenterol, 2007, 102(5): 951-956.
Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardiisupplementation on Helicobacter pylori eradication rates and side effects during treatment[J]. Aliment Pharmacol Ther, 2010, 32(9): 1069-1079.
[14]
Tong JL, Ran ZH, Shen J, et al. Meta-analysis: the effect of supplementation with probiotics on eradicationrates and adverse events during Helicobacter pylori eradication therapy[J]. Aliment Pharmacol Ther, 2007, 25(2): 155-168.
